Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis - PubMed (original) (raw)

Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis

R S Warren et al. J Clin Invest. 1995 Apr.

Abstract

To investigate the relationship between angiogenesis and hepatic tumorigenesis, we examined the expression of vascular endothelial growth factor (VEGF) in 8 human colon carcinoma cell lines and in 30 human colorectal cancer liver metastases. Abundant message for VEGF was found in all tumors, localized to the malignant cells within each neoplasm. Two receptors for VEGF, KDR and flt1, were also demonstrated in most of the tumors examined. KDR and flt1 mRNA were limited to tumor endothelial cells and were more strongly expressed in the hepatic metastases than in the sinusoidal endothelium of the surrounding liver parenchyma. VEGF monoclonal antibody administration in tumor-bearing athymic mice led to a dose- and time-dependent inhibition of growth of subcutaneous xenografts and to a marked reduction in the number and size of experimental liver metastases. In hepatic metastases of VEGF antibody-treated mice, neither blood vessels nor expression of the mouse KDR homologue flk-1 could be demonstrated. These data indicate that VEGF is a commonly expressed angiogenic factor in human colorectal cancer metastases, that VEGF receptors are up-regulated as a concomitant of hepatic tumorigenesis, and that modulation of VEGF gene expression or activity may represent a potentially effective antineoplastic therapy in colorectal cancer.

PubMed Disclaimer

Similar articles

• Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
  Bruns CJ, Liu W, Davis DW, Shaheen RM, McConkey DJ, Wilson MR, Bucana CD, Hicklin DJ, Ellis LM. Bruns CJ, et al. Cancer. 2000 Aug 1;89(3):488-99. Cancer. 2000. PMID: 10931447
• KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells.
  Yoshiji H, Kuriyama S, Hicklin DJ, Huber J, Yoshii J, Miyamoto Y, Kawata M, Ikenaka Y, Nakatani T, Tsujinoue H, Fukui H. Yoshiji H, et al. Hepatology. 1999 Nov;30(5):1179-86. doi: 10.1002/hep.510300509. Hepatology. 1999. PMID: 10534339
• Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
  Yano S, Herbst RS, Shinohara H, Knighton B, Bucana CD, Killion JJ, Wood J, Fidler IJ. Yano S, et al. Clin Cancer Res. 2000 Mar;6(3):957-65. Clin Cancer Res. 2000. PMID: 10741721
• The role of vascular endothelial growth factor in angiogenesis.
  Ferrara N, Gerber HP. Ferrara N, et al. Acta Haematol. 2001;106(4):148-56. doi: 10.1159/000046610. Acta Haematol. 2001. PMID: 11815711 Review.
• Endothelial receptor tyrosine kinases involved in blood vessel development and tumor angiogenesis.
  Breier G. Breier G. Adv Exp Med Biol. 2000;476:57-66. doi: 10.1007/978-1-4615-4221-6_5. Adv Exp Med Biol. 2000. PMID: 10949655 Review. No abstract available.

Cited by

• Inhibition of Growth and Metastasis of Tumor in Nude Mice after Intraperitoneal Injection of Bevacizumab.
  Zhao ZX, Li X, Liu WD, Liu XZ, Wu SJ, Hu XH. Zhao ZX, et al. Orthop Surg. 2016 May;8(2):234-40. doi: 10.1111/os.12236. Orthop Surg. 2016. PMID: 27384733 Free PMC article.
• Visualization of tumor angiogenesis using MR imaging contrast agent Gd-DTPA-anti-VEGF receptor 2 antibody conjugate in a mouse tumor model.
  Jun HY, Yin HH, Kim SH, Park SH, Kim HS, Yoon KH. Jun HY, et al. Korean J Radiol. 2010 Jul-Aug;11(4):449-56. doi: 10.3348/kjr.2010.11.4.449. Epub 2010 Jun 21. Korean J Radiol. 2010. PMID: 20592929 Free PMC article.
• Serial magnetic resonance spectroscopy reveals a direct metabolic effect of cediranib in glioblastoma.
  Kim H, Catana C, Ratai EM, Andronesi OC, Jennings DL, Batchelor TT, Jain RK, Sorensen AG. Kim H, et al. Cancer Res. 2011 Jun 1;71(11):3745-52. doi: 10.1158/0008-5472.CAN-10-2991. Epub 2011 Apr 20. Cancer Res. 2011. PMID: 21507932 Free PMC article. Clinical Trial.
• Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer.
  Landriscina M, Cassano A, Ratto C, Longo R, Ippoliti M, Palazzotti B, Crucitti F, Barone C. Landriscina M, et al. Br J Cancer. 1998 Sep;78(6):765-70. doi: 10.1038/bjc.1998.575. Br J Cancer. 1998. PMID: 9743297 Free PMC article.
• Bevacizumab: a review of its use in metastatic colorectal cancer.
  McCormack PL, Keam SJ. McCormack PL, et al. Drugs. 2008;68(4):487-506. doi: 10.2165/00003495-200868040-00009. Drugs. 2008. PMID: 18318567 Review.

References

1. 1. Science. 1992 Feb 21;255(5047):989-91 - PubMed
2. 1. Cell. 1993 Mar 26;72(6):835-46 - PubMed
3. 1. Hepatology. 1992 Jun;15(6):989-97 - PubMed
4. 1. J Biol Chem. 1992 Jun 5;267(16):10931-4 - PubMed
5. 1. Microvasc Res. 1992 Jan;43(1):20-45 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • American Society for Clinical Investigation
  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information